GlassScriptPhysician profile
Danielle Evelyn Weiss
NPI 1275731515
$2,572.15
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $338 · 2022: $17.57 · 2023: $34.43 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $652.09 | 2019-2020 | |
| Celgene Corporation | $370.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.32 | 2019 | |
| Abbott Laboratories | $119.01 | 2019-2024 | Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $107.85 | 2019-2020 | |
| Incyte Corporation | $104.18 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.39 | 2019-2020 | |
| Genzyme Corporation | $89.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.58 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $69.62 | 2019-2022 | |
| Eisai INC. | $66.13 | 2019 | |
| Amag Pharmaceuticals, INC. | $61.68 | 2019-2020 | |
| Seagen INC. | $56.66 | 2019-2020 | |
| Tersera Therapeutics LLC | $56.13 | 2019 | |
| Merck Sharp & Dohme LLC | $43.34 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $41.15 | 2019 | |
| Nevro Corp. | $34.43 | 2023 | Senza |
| Regeneron Healthcare Solutions, INC. | $34.02 | 2019 | |
| Clovis Oncology, INC. | $32.90 | 2019 | |
| Dendreon Pharmaceuticals LLC | $28.96 | 2020 | |
| Novo Nordisk INC | $26.38 | 2024 | Wegovy |
| Janssen Biotech, INC. | $24.97 | 2019 | |
| Astellas Pharma US INC | $24.37 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $24.22 | 2019 | |
| Daiichi Sankyo INC. | $23.48 | 2020 | |
| Shire North American Group INC | $23.18 | 2019 | |
| Spectrum Pharmaceuticals INC. | $19.84 | 2019 | |
| Dova Pharmaceuticals | $19.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.94 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.84 | 2020 | |
| Foundation Medicine, INC. | $15.26 | 2019 | |
| Kyowa Kirin, INC. | $14.55 | 2019 | |
| Blueprint Medicines Corporation | $14.51 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $12.72 | 2019 | |
| Taiho Oncology, INC. | $11.73 | 2019 | |
| Tactile Systems Technology INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.